Study on urological cancer diagnosis, prediction for stage and treatment effect by comprehensive serum glycopeptide spectra analysis(prostate cancer, urothelial cancer, renal cell carcinoma)

Study on urological cancer diagnosis, prediction for stage and treatment effect by comprehensive serum glycopeptide spectra analysis(prostate cancer, urothelial cancer, renal cell carcinoma) - Study on urological cancer diagnosis, prediction for stage and treatment effect by comprehensive serum glycopeptide spectra analysis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042777

Enrollment

800

Registered

2023-01-01

Start date

2020-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients suspected with urological cancer, and patients with urological cancer before or after receiving treatment. 2. Patients with benign urological diseases. 3. A person who has received sufficient explanation of this research and obtained informed consent.

Exclusion criteria

Exclusion criteria: 1. Person who are considered as worsen their health condition due to blood test. 2. Person who are regarded as inappropriate for the study by the researcher.

Design outcomes

Primary

Measure	Time frame
Correlation analysis between comprehensive serum glycopeptide profile analysis and diagnosis of the presence or absence of cancer, staging, efficacy for treatment, diagnostic imaging findings, and histopathological findings	—

Countries

Japan

Contacts

Public ContactMasanori Hasegawa

Tokai University School of Medicine

hasem@tsc.u-tokai.ac.jp0463-93-1121

Outcome results